Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

About this update from Alto Neuroscience, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/fef33708960038f1776cb236c8d3580d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.KXw35X9PcQBMSuUrSbFJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMQ--/https://media.zenfs.com/en/business-wire.com/fef33708960038f1776cb236c8d3580d","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.pWdOY845GU2E1aw8tOmLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY-/https://media.zenfs.com/en/business-wire.com/fef33708960038f1776cb236c8d3580d","width":1200,"height":388}},"lazy":false},{"type":"text","content":"— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052) —","length":204,"tagName":"p","attribs":{}},{"type":"text","content":"— Alto has developed a modified-release, once-daily oral formulation of ALTO-101; the Company plans to explore partnering opportunities for this formulation —","length":158,"tagName":"p","attribs":{}},{"type":"text","content":"— Development of ALTO-207 remains the top priority for the Company; Phase 2b on track to initiate in 1H 2026 —","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., April 01, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS), and provided an update on the Company's pipeline and prioritization.","length":456,"tagName":"p"},{"type":"text","content":"ALTO-101 did not achieve statistical significance on primary electroencephalography (EEG) or cognitive endpoints versus placebo; however, the study demonstrated directional improvements across certain EEG measures, including a near-significant effect on theta-ITC (n=83, d=0.34, p=0.052) – a measure correlated with cognitive performance across datasets. In a pre-specified analysis in a more cognitively impaired subgroup (n=59), ALTO-101 exhibited nomin...

More updates from Alto Neuroscience, Inc.